摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-bromo-N-methylisoquinolin-3-amine | 1374258-76-0

中文名称
——
中文别名
——
英文名称
7-bromo-N-methylisoquinolin-3-amine
英文别名
——
7-bromo-N-methylisoquinolin-3-amine化学式
CAS
1374258-76-0
化学式
C10H9BrN2
mdl
——
分子量
237.099
InChiKey
BYVMHDODQSGSOI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    379.5±22.0 °C(Predicted)
  • 密度:
    1.555±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.1
  • 重原子数:
    13
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.1
  • 拓扑面积:
    24.9
  • 氢给体数:
    1
  • 氢受体数:
    2

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    7-bromo-N-methylisoquinolin-3-amine盐酸copper(l) iodide四(三苯基膦)钯sodium hexamethyldisilazane三乙胺 作用下, 以 四氢呋喃1,4-二氧六环乙酸乙酯 为溶剂, 反应 13.5h, 生成 N-methyl-7-{3-[4-(piperazin-1-ylmethyl)-3-(trifluoromethyl)phenoxy]prop-1-yn-1-yl}isoquinolin-3-amine hydrochloride
    参考文献:
    名称:
    Structure-Based Design of Type II Inhibitors Applied to Maternal Embryonic Leucine Zipper Kinase
    摘要:
    A novel Type II kinase inhibitor chemotype has been identified for maternal embryonic leucine zipper kinase (MELK) using structure-based ligand design. The strategy involved structural characterization of an induced DFG-out pocket by proteinligand X-ray crystallography and incorporation of a slender linkage capable of bypassing a large gate-keeper residue, thus enabling design of molecules accessing both hinge and induced pocket regions. Optimization of an initial hit led to the identification of a low-nanomolar, cell-penetrant Type II inhibitor suitable for use as a chemical probe for MELK.
    DOI:
    10.1021/ml5001273
  • 作为产物:
    描述:
    N-[(3-bromophenyl)methyl]-2,2-diethoxyacetamide 在 硫酸 作用下, 以 四氢呋喃 为溶剂, 反应 25.0h, 生成 7-bromo-N-methylisoquinolin-3-amine
    参考文献:
    名称:
    Structure-Based Design of Type II Inhibitors Applied to Maternal Embryonic Leucine Zipper Kinase
    摘要:
    A novel Type II kinase inhibitor chemotype has been identified for maternal embryonic leucine zipper kinase (MELK) using structure-based ligand design. The strategy involved structural characterization of an induced DFG-out pocket by proteinligand X-ray crystallography and incorporation of a slender linkage capable of bypassing a large gate-keeper residue, thus enabling design of molecules accessing both hinge and induced pocket regions. Optimization of an initial hit led to the identification of a low-nanomolar, cell-penetrant Type II inhibitor suitable for use as a chemical probe for MELK.
    DOI:
    10.1021/ml5001273
点击查看最新优质反应信息

文献信息

  • N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS
    申请人:Griffith David A.
    公开号:US20120108619A1
    公开(公告)日:2012-05-03
    The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein G is R 1 , R 2 and R 3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
    这项发明提供了化合物的化学式(I)或其药用可接受的盐;其中G是R1,R2和R3如本文所述;以及其药物组合物;以及在治疗受乙酰辅酶A羧化酶抑制调节的动物疾病、状况或紊乱中的使用。
  • N1/N2-lactam acetyl-CoA carboxylase inhibitors
    申请人:Griffith David A.
    公开号:US08859773B2
    公开(公告)日:2014-10-14
    The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein G is R1, R2 and R3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
    本发明提供了一种公式(I)的化合物或其药学上可接受的盐;其中G为R1,R2和R3如本文所述;其药物组成物;以及在治疗动物中由乙酰辅酶A羧化酶酶抑制调节的疾病,状况或障碍中使用它的用途。
  • N1/N2-LACTAM ACETYL-CoA CARBOXYLASE INHIBITORS
    申请人:Pfizer Inc.
    公开号:EP2632925B1
    公开(公告)日:2015-05-27
  • US8859773B2
    申请人:——
    公开号:US8859773B2
    公开(公告)日:2014-10-14
  • US8993586B2
    申请人:——
    公开号:US8993586B2
    公开(公告)日:2015-03-31
查看更多